



Early Access to IsoPlexis' Single Cell Analytics Platform Enhances Cell Therapy Program at World-renowned Research and Treatment Center

IsoPlexis' groundbreaking platform has been shown in key studies to predict patient response to cell therapy

The IsoLight[®] platform:

- profiles responses at the single cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex patient response to cancer immunotherapies
- advances high-need areas of cell therapy research, development, and manufacturing, including product characterization, immune biomarker discovery, and patient monitoring.

Branford, Connecticut. (September 20, 2018) — IsoPlexis[®] Corporation (IsoPlexis), the leading developer of single-cell analytics solutions which enables complete immune cell profiling, has placed its ground-breaking IsoLight platform at [City of Hope](#), a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. IsoPlexis provides early access to its innovative platform to leading biopharmaceutical companies, researchers, and trial centers to generate proof of concept data and to solve immediate challenges in the fast moving immune-oncology field and beyond.

The integrated, sample-to-answer IsoLight platform provides clinical and translational researchers a powerful, yet straightforward solution for establishing immune response functional-correlates-with-outcome in key therapeutic areas such as CAR-T and other cellular immunotherapies.

Sean Mackay, chief executive officer and co-founder of IsoPlexis, commented “We are thrilled to be placing an IsoLight system at City of Hope, a center at the forefront of CAR-T immunotherapy. Our goal as a company is to deliver the benefits of high dimensional, single-cell proteomic data to partners like City of Hope, and we wish to continue doing this by improving cellular characterization and clinical correlates in the fast-moving immuno-oncology field and beyond.”

Christine Brown, Ph.D., the Heritage Provider Network Professor in Immunotherapy and associate director of City of Hope's T Cell Therapeutics Research Laboratory, added “We’re very excited to be one of the first facilities to access the powerful IsoLight system. As a cancer research center with a key focus on CAR-T and other cell therapies, we feel that IsoPlexis will enable us to better characterize response and potentially predict whether cancer patients will respond to CAR-T cell therapy before treatment.”

IsoPlexis, with a key collaborator, demonstrated an improved ability to predict responses of CAR-T patients pre-infusion versus legacy technologies, in a peer-reviewed publication in the journal Blood. By combining a comprehensive-imaging-based detection engine and automated fluidics with a novel and patented sample introduction and processing microchip plus a powerful data analytics suite, the IsoLight platform meets throughput and content objectives in a way that legacy technologies cannot address, earning it the global Red Dot Design Award in 2018.

For more information about the IsoLight, please visit <http://www.isoplexis.com/products>.

ABOUT ISOPLEXIS:

Data-driven and highly-targeted immunotherapies are the future of the fight against cancer. IsoPlexis, a privately held life sciences company, develops novel **end-to-end solutions** that are accelerating the revolution in immune and cell-based treatments of cancer. The IsoLight, a next-generation analytics **platform**, profiles responses at the **single cell level** enabling researchers to generate a **precise functional patient signature** to help **predict** and **understand complex patient response** to cancer immunotherapies. IsoPlexis has **partnered** with leading biopharmaceutical companies and trial centers to generate real-world data to advance high-need areas of cell product characterization, immune biomarker discovery, and patient monitoring. The IsoLight platform was recognized as The Scientist's and Fierce Life Science's #1 innovation of 2017 for its ability to provide both single-cell sensitivity and highly multiplexed and quantitative functional ELISA detection together for the first time.

For additional information on IsoPlexis, visit <http://www.isoplexis.com> or email info@isoplexis.com.

MEDIA CONTACT:

Jon Chen
Director of Demand Generation
Telephone: 475.221.8285
jon@isoplexis.com